These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19307368)

  • 21. Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
    Petraitis V; Petraitiene R; Moradi PW; Strauss GE; Katragkou A; Kovanda LL; Hope WW; Walsh TJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2718-26. PubMed ID: 26883703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
    Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
    Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
    Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L
    Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691
    [No Abstract]   [Full Text] [Related]  

  • 24. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.
    Meletiadis J; Pournaras S; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2010 Feb; 54(2):602-9. PubMed ID: 19995928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the efficacy of a posaconazole and anidulafungin combination in a murine model of pulmonary aspergillosis due to infection with Aspergillus fumigatus.
    Bedin Denardi L; Pantella Kunz de Jesus F; Keller JT; Weiblen C; de Azevedo MI; Oliveira V; Morais Santurio J; Hartz Alves S
    Diagn Microbiol Infect Dis; 2018 Jan; 90(1):40-43. PubMed ID: 29126660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
    Silva EG; Paula CR; de Assis Baroni F; Gambale W
    Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis.
    Martin-Vicente A; Capilla J; Guarro J
    Med Mycol; 2017 Jun; 55(4):457-460. PubMed ID: 27760829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.
    Mootsikapun P; Hsueh PR; Talwar D; Co VM; Rajadhyaksha V; Ong ML
    BMC Infect Dis; 2013 May; 13():219. PubMed ID: 23676114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive pulmonary aspergillosis due to Emericella nidulans var. echinulata, successfully cured by voriconazole and micafungin.
    Yu J; Mu X; Li R
    J Clin Microbiol; 2013 Apr; 51(4):1327-9. PubMed ID: 23363828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA; Kuhn DM
    Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR; Coco BJ; Patterson TF
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model.
    Karagoz E; Ugan RA; Duzgun E; Cadirci E; Keles S; Uyanik MH; Yavan I; Turhan V
    Curr Eye Res; 2017 Feb; 42(2):225-232. PubMed ID: 27348425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
    Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
    Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients.
    Tabarsi P; Soraghi A; Marjani M; Zandian P; Baghaei P; Najafizadeh K; Droudinia A; Sarrafzadeh SA; Javanmard P; Mansouri D
    Exp Clin Transplant; 2012 Jun; 10(3):278-81. PubMed ID: 22631066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine.
    Krishnan-Natesan S; Chandrasekar PH; Manavathu EK; Revankar SG
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):443-6. PubMed ID: 18842377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
    Petraitis V; Petraitiene R; Katragkou A; Maung BBW; Naing E; Kavaliauskas P; Barat S; Borroto-Esoda K; Azie N; Angulo D; Walsh TJ
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angio-oedema as an unusual tolerable side effect of voriconazole therapy.
    Gençer S; Özer S; Demirhan G; Ak Ö; Batırel A
    J Med Microbiol; 2008 Aug; 57(Pt 8):1028-1031. PubMed ID: 18628507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid.
    Matsuda T; Koreeda Y; Mataki H; Taira T; Noma S; Higashimoto I
    Intern Med; 2010; 49(12):1163-9. PubMed ID: 20558936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
    Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.